Fierce Biotech July 18, 2022
Andrea Park

It didn’t take Delfi Diagnostics long after its 2019 founding to hit the coveted nine-digit funding mark: It reached that milestone in early 2021 with the close of its $100 million series A. Less than two years later, the liquid biopsy developer has done it again—this time with a supersized venture round that more than doubles its previous fundraising.

The new series B, clocking in at $225 million, was led by DFJ Growth, a Silicon Valley venture capital firm that’s also sending one of its partners to join Delfi’s board of directors. DFJ was joined by nearly two dozen new and existing backers including Eli Lilly & Co., Illumina’s venture arm and more.

With the funding, Delfi said it...

Today's Sponsors

Amwell
Oliver Wyman
Upfront Healthcare

Today's Sponsors

Qure4u
H1

Today's Sponsor

HealthITq

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Price and End Point. For Cancer Drugs, There Is a Disconnect, Research Finds
What makes a good (and bad) pharmaceutical forecast model
Wearables Made for the Pharmaceutical Industry
Haemostatic device developer raises $25m
Scientists discover anti-inflammatory molecules that decline in the aging brain